The Rubin lab approach to cancer research has grown in parallel with the rapid expansion of bioinformatics and sequencing technology over the past 10 years. Our expertise in identifying functional biomarkers and investigating prostate cancer heterogeneity has led to key discoveries in the distinction between indolent and aggressive cancer types. Our mission is to identify potential therapeutic targets and bridge the latest in cancer genetics research with individual patient oriented clinical care. The Rubin lab is based in Bern at the Department for BioMedical Research (DBMR), University of Bern, Switzerland.
News & Events
From Cancer Dependence to Cancer Therapeutics
William Sellers is a core institute member of the Broad Institute of MIT and Harvard, a faculty member at Harvard Medical School (HMS), and faculty member and senior advisor to the president for experimental therapeutics at Dana-Farber Cancer Institute (DFCI). He is a distinguished cancer scientist, with deep experience in cancer biology and cancer therapeutics.
Youtube - Lecture of Tuesday June 12, 2018
The Genomics of Prostate Cancer: A Historic Perspective
The long tail of oncogenic drivers in prostate cancer
Media release / MSC Fellowships, Joanna Triscott
Great success for Bern as a medical center
The Swiss Personalized Health Network (SPHN) supports nine research projects with Bernese investment, which aim to build up a nationally coordinated infrastructure of health data. Two of the projects are managed by the University of Bern and Bern University Hospital. They are funded with a total of 5.3 million francs.
Swiss Prostate Cancer Researchers
Weill Cornell Medicine Awarded
$11.3 Million Prestigious Grant for Prostate Cancer Research
A precision approach to tumour treatment
Progress is being made in the use of personalized approaches to create both
in vitro and in vivo tumour models that could be used to aid cancer drug-treatment
decisions and increase our understanding of how tumours respond to therapy.
Dr. Bishoy Faltas, MD, named AACR NextGen Star
Genomic dissection of the clonal evolution dynamics of chemotherapy-resistant urothelial carcinoma
Chemotherapy Drives Treatment Resistance in Bladder Cancer
Chemotherapy is indicated as the first line of treatment for advanced bladder cancer. New research by Weill Cornell Medicine and University of Trento scientists shows that while chemotherapy kills the most common type of bladder cancer, urothelial cancer, chemotherapy also shapes the genetic evolution of remaining urothelial cancer cell clones to become drug-resistant.
Gene Identified that Drives Aggressive Prostate Cancer
An overactive gene appears to cause some prostate cancers to transform from a typical tumor type to a much more aggressive form of the disease, according to new research at Weill Cornell Medicine.
Precision Cancer Test Validated for Clinical Usage
A powerful next-generation genome-sequencing test developed at Weill Cornell Medicine can detect mutations that guide precision cancer treatment with over 95 percent accuracy, according to new research. The scientists say their findings, published July 20 in NPJ Genomic Medicine, validate the test, called Weill Cornell Medicine EXaCT-1, and demonstrate its feasibility in a clinical setting.
NIH awards $4M grant to advance precision medicine
Moving with what has been cited as unprecedented speed, the National Institutes of Health (NIH) has chosen a collaboration of four New York institutions -- Weill Cornell Medicine, NewYork-Presbyterian Hospital, Columbia University Hospital and NYC Health + Hospitals/Harlem -- to launch a landmark longitudinal research study as a part of President Barack Obama’s Precision Medicine Initiative (PMI).
Sequencing Reveals Underpinnings of Aggressive Prostate Cancer Subtype
A subset of treatment-resistant prostate cancer pathologically resembles small cell lung cancer rather than typical prostate cancer, Weill Cornell Medicine and University of Trento investigators discovered in a new study. The scientists say their findings may lead to more effective ways to diagnose and treat neuroendocrine prostate cancer
Researchers Validate Precision Medicine Approach Using New Whole Exome Sequencing Test
Much of precision medicine and cancer care focuses on targeting the genomes of specific tumors or metastases. At Weill Cornell Medical College, a research team has now shown that a more global look at the body using next-generation sequencing can offer new insights — and targets — in patients with advanced, treatment-resistant disease.
Health: Make precision medicine work for cancer care
To get targeted treatments to more cancer patients pair genomic data with clinical data, and make the information widely accessible, urges Mark A. Rubin.
Big Data Key to Precision Medicine's Success
Technological advances are enabling scientists to sequence the genomes of cancer tumors, revealing a detailed portrait of genetic mutations that drive these diseases